[Solifenacin in the treatment of overactive bladder: results of a randomized double-blind, placebo-controlled study].
The article presents the results of the evaluation of clinical efficacy and safety of the M-cholinoblocker solifenacin in the treatment of symptoms of overactive bladder (OAB). The study included 24 women aged from 47 to 69 years with symptoms of OAB lasting more than 3 months. It is shown that solifenacin at a dose of 5 mg reduces the quality of urinary urgency, improves the condition according to assessment of degree of discomfort due to symptoms of the OAB, treatment satisfaction and condition of the bladder.